# pleural mesothelioma stages

National Comprehensive Cancer Network - Home » The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives. NCCN offers a number of programs to give clinicians access to tools and knowledge that can help guide decision-making in the management of cancer. Nccn.org

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline » Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with ma Ascopubs.org

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ » Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in exposures with world-standardised incidence rates per 100 000 persons of 0.7 and 0.3 in the United States and 1.7 and 0.4 for Europe (for males and females, respectively). Incidence is highest in countries with greatest previous asbestos use such as the Netherlands, UK and Australia.1 Due to a lag time of ∼40 years between exposure and presentation, alongside relatively recent usage bans, incidence continues to rise in many countries. Annalsofoncology.org

Current chemotherapy strategies in malignant pleural mesothelioma » Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a 5-year survival rate of ~10%. Since most patients present with irresectable disease, the vast majority is treated with chemotherapy. The only registered therapy for MPM is platinum-pemetrexed… Ncbi.nlm.nih.gov

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study - PubMed » Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was administered according to a groupwise dose escalation schedule (group A, 3 x 10(4); group B, 3 x 10(5); … Pubmed.ncbi.nlm.nih.gov

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma » Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known… Ncbi.nlm.nih.gov